Nexalin names Abbott, Medtronic veteran Robert DiTota senior strategic advisor for global commercialization
Bitget2026/09/29 13:05- Nexalin Technology appointed neuromodulation executive Robert DiTota as senior strategic advisor for global commercialization, effective Sept. 15, 2026.
- DiTota will advise management on commercial strategy, international distribution, market development, go-to-market planning, commercial infrastructure, organizational buildout.
- He spent more than 20 years in neuromodulation at Abbott, most recently divisional VP of sales for North America commercial neuromodulation.
- DiTota previously worked at Medtronic for nine years, supporting deep brain stimulation in New York and the Activa platform launch.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
